P53 isoform profiling in glioblastoma and injured brain

Oncogene

Volumn 32, Issue 26, 2013, Pages 3165-3174

  Takahashi, R ^a,b   Giannini, C ^a   Sarkaria, J N ^a   Schroeder, M ^a   Rogers, J ^c   Mastroeni, D ^c   Scrable, H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

astrocytoma; gliosis; regeneration

Indexed keywords

PROTEIN P53;

ADULT; AGED; ANIMAL CELL; ARTICLE; BRAIN INJURY; CANCER TISSUE; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MOUSE; NEURAL STEM CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ASTROCYTOMA; BRAIN INJURIES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CEREBRAL CORTEX; FEMALE; GLIOBLASTOMA; GLIOSIS; HUMANS; MALE; MICE; MIDDLE AGED; MUTATION; MUTATION RATE; NEOPLASM TRANSPLANTATION; PROTEIN ISOFORMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879685153     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.322     Document Type: Article

References (61)

1. Machado-SilvaA, PerrierS, BourdonJC.p53 family members in cancer diagnosis and treatment. Semin Cancer Biol 2010; 20: 57-62.
2. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010; 2: a001016.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
5. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
6. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
7. Butler T, Gribben JG. Biologic and clinical significance of molecular profiling in chronic lymphocytic leukemia. Blood Rev 2010; 24: 135-141.
8. Li W, Sanki A, Karim RZ, Thompson JF, Soon Lee C, Zhuang L et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006; 38: 287-301.
9. Soussi T. The TP53 web site. Paris 2010 [updated July 2010; cited 2011 September 10]; Available from http://p53.free.fr/Database/p53-cancer-db.html.
10. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994; 54: 649-652.
11. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006; 12: 3985-3992.
12. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 2008; 14: 1659-1668.
13. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007; 43: 617-623.
14. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-2137.
15. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A et al. Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett 2010; 584: 4463-4468.
16. Ungewitter E, Scrable H. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 2010; 24: 2408-2419.
17. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004; 24: 7987-7997.
18. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 21: 6722-6728.
19. Philipova T, Baryawno N, Hartmann W, Pietsch T, Druid H, Johnsen JI et al. Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts. Int J Oncol 2011; 38: 843-849.
20. Khoury MP, Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2010; 2: a000927.
21. Mills AA. p53: link to the past, bridge to the future. Genes Dev 2005; 19: 2091-2099.
22. Rovinski B, Munroe D, Peacock J, Mowat M, Bernstein A, Benchimol S. Deletion of 50-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol Cell Biol 1987; 7: 847-853.
23. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 2002; 4: 462-467.
24. Ray PS, Grover R, Das S. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 2006; 7: 404-410.
25. Grover R, Candeias MM, Fahraeus R, Das S. p53 and little brother p53/47: linking IRES activities with protein functions. Oncogene 2009; 28: 2766-2772.
26. Matlashewski G, Pim D, Banks L, Crawford L. Alternative splicing of human p53 transcripts. Oncogene Res 1987; 1: 77-85.
27. Candeias MM, Powell DJ, Roubalova E, Apcher S, Bourougaa K, Vojtesek B et al. Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene 2006; 25: 6936-6947.
28. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007; 43: 617-623.
29. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
30. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993; 3: 255-268.
31. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
32. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-822.
33. Globus J, Kulenbeck H. Tumors of the striatothalamic and related regions: their probable source of origin and more common forms. Arch Pathol 1942; 24: 674-734.
34. Globus J, Kuhlenbeck H. The subependymal cell plate (matrix) and its relationship to brain tumors of the ependymal type. J Neuropathol Exp Neurol 1944; 3: 1-35.
35. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK et al. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 1999; 96: 10361-10366.
36. Doetsch F, Petreanu L, Caille I, Garcia-Verdugo JM, Alvarez-Buylla A. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 2002; 36: 1021-1034.
37. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000; 425: 479-494.
38. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
39. Leonard BW, Mastroeni D, Grover A, Liu Q, Yang K, Gao M et al. Subventricular zone neural progenitors from rapid brain autopsies of elderly subjects with and without neurodegenerative disease. J Comp Neurol 2009; 515: 269-294.
40. Medrano S, Burns-Cusato M, Atienza MB, Rahimi D, Scrable H. Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53. Neurobiol Aging 2009; 30: 483-497.
41. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell 1990; 60: 585-595.
42. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999; 97: 703-716.
43. Laywell ED, Kukekov VG, Steindler DA. Multipotent neurospheres can be derived from forebrain subependymal zone and spinal cord of adult mice after protracted postmortem intervals. Exp Neurol 1999; 156: 430-433.
44. Imura T, Kornblum HI, Sofroniew MV. The predominant neural stem cell isolated from postnatal and adult forebrain but not early embryonic forebrain expresses GFAP. J Neurosci 2003; 23: 2824-2832.
45. Imura T, Nakano I, Kornblum HI, Sofroniew MV. Phenotypic and functional heterogeneity of GFAP-expressing cells in vitro: differential expression of LeX/CD15 by GFAP-expressing multipotent neural stem cells and non-neurogenic astrocytes. Glia 2006; 53: 277-293.
46. Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci 2004; 7: 1233-1241.
47. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. Cellular composition and threedimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 1997; 17: 5046-5061.
48. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci 1992; 12: 4565-4574.
49. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255: 1707-1710.
50. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGFresponsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 1996; 175: 1-13.
51. Gard AL, Pfeiffer SE. Two proliferative stages of the oligodendrocyte lineage (A2B5p O4 and O4pGalC) under different mitogenic control. Neuron 1990; 5: 615-625.
52. Buffo A, Rite I, Tripathi P, Lepier A, Colak D, Horn AP et al. Origin and progeny of reactive gliosis: a source of multipotent cells in the injured brain. Proc Natl Acad Sci USA 2008; 105: 3581-3586.
53. Lang B, Liu HL, Liu R, Feng GD, Jiao XY, Ju G. Astrocytes in injured adult rat spinal cord may acquire the potential of neural stem cells. Neuroscience 2004; 128: 775-783.
54. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
55. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
56. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
57. Sasaki T, Maier B, Bartke A, Scrable H. Progressive loss of SIRT1 with cell cycle withdrawal. Aging Cell 2006; 5: 413-422.
58. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol 2011; 52: 1-14.
59. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13: 962-972.
60. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC et al. Frequent coalterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
61. Gritti A, Galli R, Vescovi A. Protocols for Neural Cell Culture. 3rd edn. Fedoroff S, Richardson A (eds). Humana Press, Inc: Totowa, 2001.